Short answer
Idexx Laboratories (IDXX) filed its Q3 2025 10-Q quarterly report on Nov 3, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $1.1B (up 13.3% year over year) with net income of $275M.
Q3 2025 key financials · XBRL
- Revenue
- $1.1B
- +13.3% YoY · −0.4% QoQ
- Net income
- $275M
- +17.9% YoY · −6.6% QoQ
- Operating margin
- 32.1%
- Gross margin
- 61.8%
- EPS (diluted)
- $3.40
- +21.0% YoY · −6.3% QoQ
Source: XBRL data from the Idexx Laboratories (IDXX) Q3 2025 10-Q on SEC EDGAR. USD.
Idexx Laboratories Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- No profitability or margin percentages provided
- No segment or product line performance details mentioned
- No changes in cash position, operating cash flow, or capital deployment reported
- No management commentary on near-term outlook or guidance given
Risk Factors
- No material changes in risk factors since 2024 Annual Report
- Ongoing risks include business, financial condition, or future results impact
- Potential for unknown or currently immaterial risks to materially affect performance
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Idexx Laboratories quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.